When a drug's patent expires, the company that invented it no longer has a monopoly. This allows other manufacturers to step in. While this is great for your wallet and the healthcare system, it creates a massive financial hole for the original developers. To understand the scale, look at the 2025-2030 window: over 65 different drug products with annual sales exceeding $100 million are set to lose exclusivity. That is nearly $187 billion in revenue at risk.
The 2025-2030 Expiration Timeline
Not all expirations happen at once, and the impact varies depending on what the drug actually is. Some are small-molecule drugs (simple chemical structures), while others are biologics (complex proteins grown in living cells). Here is the breakdown of the heavy hitters we need to watch.
In July 2025, we hit a major milestone with Entresto is a cardiovascular medication used to treat heart failure. With global sales hitting $7.8 billion in 2024, its core combination patent (US8329752) expires in the U.S. mid-year. For patients, this is huge. Some are currently paying up to $300 monthly; generics could feasibly drop that to $20-$40.
Moving into 2026, the focus shifts to anticoagulants. Eliquis is a blockbuster blood thinner developed by Bristol Myers Squibb and Pfizer. Its key crystalline form patent (US8278323) expires in November 2026. Given its $13.2 billion annual revenue, the entry of generics will likely cause a rapid price crash because the market for anticoagulants is already crowded with alternatives.
Then comes the "big one" in 2028. Keytruda is a powerhouse immunotherapy drug used to treat various cancers. Generating over $29 billion in 2024 alone, its core composition-of-matter patent expires in 2028. Analysts predict this will be the single largest revenue decline in pharma history, potentially wiping out $15 billion in annual revenue for Merck within 18 months of generic entry.
| Drug Name | Therapeutic Area | Expiring Patent/Date | Approx. 2024 Revenue |
|---|---|---|---|
| Entresto | Cardiovascular | July 2025 | $7.8 Billion |
| Eliquis | Cardiovascular | November 2026 | $13.2 Billion |
| Keytruda | Oncology | 2028 | $29.3 Billion |
Generics vs. Biosimilars: Why the Wait Varies
You might wonder why some drugs become cheap overnight while others take years. It comes down to the chemistry. Small-molecule drugs are like baking a cake from a recipe; once the patent is gone, any competent bakery can make an identical version. These typically see a 80-90% price drop within a year.
Biologics, however, are more like growing a specific type of rare orchid. They are incredibly complex. Instead of generics, we get Biosimilars is biological products that are highly similar to an approved reference biologic. Because they are harder to manufacture, the price drops are slower-usually only 30-40% initially-and it takes 3-5 years to capture a significant market share.
This complexity creates a "patent thicket." While a small-molecule drug might have 14 patents protecting it, a biologic can have over 130. This allows companies to fight in court for years, delaying the arrival of cheaper versions by an average of 2.3 years.
How the Industry is Fighting Back
Pharmaceutical companies aren't just sitting around waiting for their revenue to vanish. They use a few specific strategies to keep their profits flowing:
- Evergreening: This is when a company makes a slight change to the drug-like a new extended-release version or a different delivery device-and files a new patent to extend their exclusivity.
- Patent Thickets: Filing dozens of overlapping patents on every tiny detail of the drug's formulation to make it too expensive or legally risky for generic companies to challenge.
- M&A Sprees: When a company knows a big earner is expiring, they buy other companies to fill the gap. For example, Bristol Myers Squibb spent $4.1 billion on Karuna Therapeutics to boost their neuroscience portfolio before Eliquis loses protection.
However, the Federal Trade Commission is the U.S. agency responsible for consumer protection and antitrust law. They are cracking down on "pay-for-delay" agreements-where brand-name companies pay generic makers to stay off the market. Investigations into these settlements have increased by 23% recently.
What This Means for Patients and Providers
For the average person, the patent cliff is a massive win for accessibility. The Congressional Budget Office estimates that these expirations could save the U.S. healthcare system $312 billion over the next decade. If you're a patient on a high-cost biologic or heart medication, the window between 2025 and 2027 is the time to talk to your doctor about upcoming alternatives.
Doctors and pharmacists are already prepping. Many hospital systems are implementing "early switch" programs to move patients to generics the moment they are approved. In the U.S., the FDA Orange Book is the gold standard for tracking small-molecule expirations, while the Purple Book handles biologics. If you're a healthcare provider, these are the tools you need to navigate the transition.
But it's not all smooth sailing. We might see initial shortages. When a drug like Entresto goes generic, demand spikes instantly. We saw this happen with Humira biosimilars, where the sudden shift in supply chains led to temporary gaps in availability. Pharmacy technicians are already warning that we should expect similar hiccups in 2025.
The Long-Term Outlook
Will this destroy the pharma industry? Not exactly. While the top 10 companies might consolidate into a smaller group through mergers, innovation is shifting. We're seeing a massive move toward gene therapies and targeted oncology. These new frontiers are creating a new generation of patents that will offset some of the losses from the 2025-2030 cliff.
In the end, the cycle of innovation and expiration is what keeps the industry moving. The high prices of today's blockbusters fund the research for tomorrow's cures, while the expirations of yesterday's blockbusters make healthcare affordable for the masses. The next five years will be a chaotic but necessary transition.
What is a pharmaceutical patent cliff?
A patent cliff occurs when one or more blockbuster drugs lose their patent protection, allowing generic or biosimilar versions to enter the market. This typically leads to a sharp decline in revenue for the original manufacturer and a significant price drop for patients.
Which drug expiration will have the biggest impact?
Keytruda is expected to have the largest single impact due to its massive annual revenue (over $29 billion in 2024). Its core patent expiration in 2028 could result in a loss of $15 billion in annual revenue for Merck within a short period.
How are biosimilars different from generics?
Generics are exact chemical copies of small-molecule drugs. Biosimilars are nearly identical versions of complex biological drugs. Because biologics are harder to make, biosimilars take longer to reach the market and usually don't offer as deep a price discount as small-molecule generics.
When will generic Entresto be available?
The core combination patent for Entresto expires in July 2025 in the United States. Generic versions are expected to enter the market around that time, though some regulatory approvals for components have already begun.
Will these expirations really lower healthcare costs?
Yes. The Congressional Budget Office estimates a reduction in national healthcare spending by $312 billion over the decade, with a large portion of those savings occurring between 2025 and 2027 as the first wave of blockbusters expires.
Next Steps and Troubleshooting
For Patients: If you are taking a medication that is nearing its expiration (like Entresto), start a conversation with your doctor now. Ask about the expected timeline for generics and if your insurance provider has a plan for switching to a more affordable version.
For Providers: Review the FDA Orange Book and Purple Book regularly. If you manage a clinic or hospital pharmacy, begin adjusting your inventory and formulary policies at least six months before a major expiration to avoid the supply chain shocks seen in previous biosimilar launches.
For Investors: Monitor M&A activity. Companies with high exposure to the 2025-2030 cliff (like Amgen or Merck) will likely engage in aggressive acquisitions to diversify their portfolios. Look for shifts toward neuroscience and gene therapy as indicators of long-term viability.
